PE20231168A1 - Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents

Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Info

Publication number
PE20231168A1
PE20231168A1 PE2023000189A PE2023000189A PE20231168A1 PE 20231168 A1 PE20231168 A1 PE 20231168A1 PE 2023000189 A PE2023000189 A PE 2023000189A PE 2023000189 A PE2023000189 A PE 2023000189A PE 20231168 A1 PE20231168 A1 PE 20231168A1
Authority
PE
Peru
Prior art keywords
glucopyranosidase
desoxy
acetamido
glycoprotein
inhibitor
Prior art date
Application number
PE2023000189A
Other languages
English (en)
Spanish (es)
Inventor
Asmerom Weldeab
Tae Kim Correia
Aireal Diane Jenkins
Yiqing Lin
Chaomin Li
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PE20231168A1 publication Critical patent/PE20231168A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
PE2023000189A 2020-08-03 2021-08-03 Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa PE20231168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063060281P 2020-08-03 2020-08-03
PCT/US2021/044341 WO2022031701A1 (en) 2020-08-03 2021-08-03 Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor

Publications (1)

Publication Number Publication Date
PE20231168A1 true PE20231168A1 (es) 2023-07-26

Family

ID=77640732

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000189A PE20231168A1 (es) 2020-08-03 2021-08-03 Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Country Status (18)

Country Link
US (1) US20230286972A1 (https=)
EP (1) EP4188925A1 (https=)
JP (1) JP7789056B2 (https=)
KR (1) KR20230061395A (https=)
CN (1) CN116917284A (https=)
AR (1) AR123132A1 (https=)
AU (1) AU2021322186A1 (https=)
BR (1) BR112023002013A2 (https=)
CA (1) CA3188250A1 (https=)
CL (1) CL2023000327A1 (https=)
CO (1) CO2023002543A2 (https=)
CR (1) CR20230118A (https=)
IL (1) IL300365A (https=)
MX (1) MX2023001469A (https=)
PE (1) PE20231168A1 (https=)
TW (1) TW202220984A (https=)
UY (1) UY39366A (https=)
WO (1) WO2022031701A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2602139B (en) * 2020-12-18 2024-07-24 Nexeon Ltd Electroactive materials for metal-ion batteries
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3555087A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
US12180205B2 (en) * 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Also Published As

Publication number Publication date
TW202220984A (zh) 2022-06-01
CN116917284A (zh) 2023-10-20
US20230286972A1 (en) 2023-09-14
AU2021322186A1 (en) 2023-04-06
BR112023002013A2 (pt) 2023-05-02
MX2023001469A (es) 2023-06-16
EP4188925A1 (en) 2023-06-07
CR20230118A (es) 2023-06-02
CA3188250A1 (en) 2022-02-10
CO2023002543A2 (es) 2023-06-09
JP7789056B2 (ja) 2025-12-19
UY39366A (es) 2022-02-25
CL2023000327A1 (es) 2023-10-06
JP2023536911A (ja) 2023-08-30
IL300365A (en) 2023-04-01
WO2022031701A1 (en) 2022-02-10
AR123132A1 (es) 2022-11-02
KR20230061395A (ko) 2023-05-08
WO2022031701A9 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
AR125818A1 (es) Inhibidores de nlrp3
PE20161396A1 (es) Compuesto heterociclico
PE20231168A1 (es) Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa
AR065867A1 (es) Compuestosde isoxazolina y su uso en el control de plagas
CO6290763A2 (es) Derivados de benzamidas, carboxamidas y nicotinamidas como moduladores alostericos positivos y sus composiciones
MX2022010040A (es) Compuestos moduladores de gcn2.
AR038382A1 (es) Compuesto inhibidor de la hepatitis c
AR052132A1 (es) Polimorfos de {5-[3-(4,6-difloruro-1h- benzoimidazol-2-il)-1h-indazol-5-il]-4- metil-piridin-3- ilmetil}-etil- amina
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR062366A1 (es) Derivados de pirazoles como inhibidores no nucleosidicos de la transcriptasa inversa, composiciones farmaceuticas
MX368680B (es) Administración subcutánea de un derivado de isoxazol-benzamida para usarse en un método para proteger un mamífero de una pulga.
ECSP109919A (es) Compuesto de piridacina cristalina
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
PE20110941A1 (es) 2-[(5-cloro-2-{[3-metil-1-(1-metiletil)-1h-pirazol-5-il]amino}-4-piridinil)amino]-n-(metiloxi)benzamida como inhibidor fak
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
EA200200819A1 (ru) Кристаллическая форма ii линезолида
AR066972A1 (es) Derivados azapeptidicos
ES2678086T3 (es) Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos
MX2023006194A (es) Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo.
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
CL2025001654A1 (es) Compuestos novedosos como moduladores de la inhibición de nlrp3
EA202190046A1 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
AR063636A1 (es) Derivados de indol y de benzofurano-2-carboxamida